Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients.
Webb MJ, Neth BJ, Webb LM, Van Gompel JJ, Link MJ, Neff BA, Carlson ML, Driscoll CL, Dornhoffer J, Ruff MW, Anderson KA, Kizilbash SH, Campian JL, Uhm JH, Lane JI, Benson JC, Blezek DJ, Mehta PM, Bathla G, Sener UT. Webb MJ, et al. Among authors: campian jl. Neurooncol Adv. 2023 Sep 22;5(1):vdad123. doi: 10.1093/noajnl/vdad123. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37841698 Free PMC article.
Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas.
Riviere-Cazaux C, Lacey JM, Carlstrom LP, Laxen WJ, Munoz-Casabella A, Hoplin MD, Ikram S, Zubair AB, Andersen KM, Warrington AE, Decker PA, Kaufmann TJ, Campian JL, Eckel-Passow JE, Kizilbash SH, Tortorelli S, Burns TC. Riviere-Cazaux C, et al. Among authors: campian jl. Neurooncol Adv. 2023 May 11;5(1):vdad061. doi: 10.1093/noajnl/vdad061. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37313502 Free PMC article. No abstract available.
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. Brastianos PK, et al. N Engl J Med. 2023 Jul 13;389(2):118-126. doi: 10.1056/NEJMoa2213329. N Engl J Med. 2023. PMID: 37437144 Free PMC article. Clinical Trial.
A case series of osseous metastases in patients with glioblastoma.
Webb LM, Webb MJ, Campian JL, Caron SJ, Ruff MW, Uhm JH, Sener U. Webb LM, et al. Among authors: campian jl. Medicine (Baltimore). 2024 Jul 5;103(27):e38794. doi: 10.1097/MD.0000000000038794. Medicine (Baltimore). 2024. PMID: 38968484 Free PMC article.
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
Sarkaria JN, Ballman KV, Kizilbash SH, Sulman EP, Giannini C, Friday BB, Butowski NA, Mohile NA, Piccioni DE, Battiste JD, Drappatz J, Campian JL, Mashru S, Jaeckle KA, O'Brien BJ, Dixon JG, Kabat BF, Laack NL, Hu LS, Kaufmann T, Kumthekar P, Ellingson BM, Anderson SK, Galanis E. Sarkaria JN, et al. Among authors: campian jl. JAMA Oncol. 2024 Dec 1;10(12):1637-1644. doi: 10.1001/jamaoncol.2024.4361. JAMA Oncol. 2024. PMID: 39480453 Clinical Trial.
Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA.
Riviere-Cazaux C, Dong X, Mo W, Kumar R, Dai C, Carlstrom LP, Munoz-Casabella A, Ghadimi K, Nesvick CL, Andersen KM, Hoplin MD, Canaday N, Jusue-Torres I, Malik N, Campian JL, Ruff MW, Uhm JH, Eckel-Passow JE, Kaufmann TJ, Routman DM, Kizilbash SH, Sener U, Warrington AE, Jenkins RB, Du P, Jia S, Burns TC. Riviere-Cazaux C, et al. Among authors: campian jl. Clin Cancer Res. 2024 Dec 23. doi: 10.1158/1078-0432.CCR-24-1814. Online ahead of print. Clin Cancer Res. 2024. PMID: 39715486
A Hitchhiker's Guide Toward CSF Biomarkers for Neuro-Oncology.
Riviere-Cazaux C, Keough MB, Zuccato JA, Kumar R, Schulz S, Warrington AE, Ruff MW, Ellingson BM, Sanai N, Campian JL, Kizilbash SH, Parney IF, Zadeh G, Khasraw M, Kessler T, Sener U, Cahill DP, Mansouri A, Burns TC. Riviere-Cazaux C, et al. Among authors: campian jl. Neuro Oncol. 2024 Dec 30:noae276. doi: 10.1093/neuonc/noae276. Online ahead of print. Neuro Oncol. 2024. PMID: 39786477
A field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery.
Riviere-Cazaux C, Graser CJ, Warrington AE, Hoplin MD, Andersen KM, Malik N, Palmer EA, Carlstrom LP, Dasari S, Munoz-Casabella A, Ikram S, Ghadimi K, Himes BT, Jusue-Torres I, Sarkaria JN, Meyer FB, Van Gompel JJ, Kizilbash SH, Sener U, Michor F, Campian JL, Parney IF, Burns TC. Riviere-Cazaux C, et al. Among authors: campian jl. Neuro Oncol. 2024 Dec 30:noae277. doi: 10.1093/neuonc/noae277. Online ahead of print. Neuro Oncol. 2024. PMID: 39786485
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Fain Shmueli S; GLOBE Study Investigators; Wen PY. Cloughesy TF, et al. Among authors: campian jl. Neuro Oncol. 2020 May 15;22(5):705-717. doi: 10.1093/neuonc/noz232. Neuro Oncol. 2020. PMID: 31844890 Free PMC article. Clinical Trial.
83 results